Credit Suisse Downgrades PDL BioPharma (PDLI) to Underperform
Tweet Send to a FriendGet Alerts PDLI Hot Sheet
Price: $8.35 +1.09%
Rating Summary:
1 Buy, 4 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Rating Summary:
1 Buy, 4 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Trade PDLI Now!
Credit Suisse downgraded PDL BioPharma (NASDAQ: PDLI) from Neutral to Underperform.
For an analyst ratings summary and ratings history on PDL BioPharma click here. For more ratings news on PDL BioPharma click here.
Shares of PDL BioPharma closed at $7.42 yesterday, with a 52 week range of $6.02-$8.43.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For an analyst ratings summary and ratings history on PDL BioPharma click here. For more ratings news on PDL BioPharma click here.
Shares of PDL BioPharma closed at $7.42 yesterday, with a 52 week range of $6.02-$8.43.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Exane BNP Paribas Downgrades BlackBerry (BBRY) to Underperform; Analyst Says Profit 'Drying Up'
- Jefferies Lifts Numbers on Diana Shipping (DSX) Post Q1
- BGC Partners Downgrades DuPont (DD) to Sell
Create E-mail Alert Related Categories
DowngradesRelated Entities
Credit Suisse
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
